You see the science; your patients feel the results. A problem this intimate, deserves a device this innovative.
VIVEVE® is a women’s intimate health company commercialising an innovative, clinically proven, proprietary platform technology (CMRF) to address multiple unmet medical needs. The Viveve® System is the only dual-mode device in its class specifically designed to renew vaginal tissue and is approved in over 60 countries.
Lasers directly impact epithelial layers but can’t penetrate to the deeper layers of connective tissue. Treating laxity requires volumetric heating in the connective tissue layers, therefore sustained RF energy is required.
The Viveve® System incorporates active cooling along with monopolar radiofrequency CMRF energy to create a reverse thermal gradient that cools and protects the surface tissue while delivering significant heat to the deeper tissue layers, resulting in a therapeutic endpoint that is achieved with a single treatment.
Women worldwide are increasingly demanding nonsurgical gynecologic treatments. However, there are a limited number of safe and effective technologies specifically designed for women’s intimate health. Viveve® provides clinically proven, innovative, nonsurgical treatments to improve women’s intimate health.
The Viveve® System was tested in three prospective clinical trials; one in the U.S., one in Japan and a large, multi-center randomized, sham controlled global clinical trial. The studies assessed the safety, effectiveness and meaningful benefit of the treatment. In all trials, statistically significant and sustained results were found.
The Viveve® System is indicated for treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function in Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Hong Kong, Japan, Malaysia, Panama, Philippines, Singapore, United Arab Emirates. The Viveve® System is indicated for the treatment of vaginal laxity in the EU, Iceland, Korea, Lebanon, Liechtenstein, Norway, Switzerland, Turkey. The Viveve® System is indicated for use in General Surgical procedures for electrocoagulation and hemostasis in Thailand, and the United States.
For more information contact:
Regional Sales Manager-UK
+44 (0) 7340.124.762